Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!


FDA appeals “morning after” pill ruling

Agency seeks to overturn ruling requiring it to make pill available over-the-counter to women of all ages

The Food and Drug Administration (FDA) is fighting back against a recent decision that struck down restrictions on the “morning after” pill.

Last month, a district judge ordered the FDA to make the emergency contraception pill available to women of all ages and without a prescription within 30 days. Currently, the government enforces age restrictions on nonprescription sales of the morning-after pill to girls who are 16 years old or younger. Reproductive rights advocates have long petitioned the FDA to strike down the restrictions, saying there is no scientific proof that girls younger than 17 couldn’t safely use the drug without supervision.

Facing the 30-day deadline, the FDA yesterday filed an appeal with the 2nd Circuit. The Department of Justice also asked the district court for a temporary injunction on the order while the appeal is pending.

Read more at Thomson Reuters.

For more InsideCounsel stories about legal battles over contraception, read:

Judge strikes down restrictions on “morning after” pill

Federal Circuit invalidates Bayer’s Yaz patent

Bayer settles claims of gallbladder injury caused by Yasmin and Yaz contraceptives

Bayer designates $1.5 billion for litigation over Yasmin and Yaz contraceptives

Court denies contraception coverage injunction

Birth control exemptions fail to stop lawsuits

Hobby Lobby loses appeal of contraception coverage

Hobby Lobby must cover morning-after pill, judge rules

Obamacare faces another lawsuit over contraception coverage

Woman sues birth control pill maker for unintended pregnancy

Ashley Post

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.